192 related articles for article (PubMed ID: 28802906)
21. From genetics to the clinic: a translational perspective on follicular lymphoma.
Huet S; Sujobert P; Salles G
Nat Rev Cancer; 2018 Apr; 18(4):224-239. PubMed ID: 29422597
[TBL] [Abstract][Full Text] [Related]
22. Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases.
Callet-Bauchu E; Baseggio L; Felman P; Traverse-Glehen A; Berger F; Morel D; Gazzo S; Poncet C; Thieblemont C; Coiffier B; Magaud JP; Salles G
Leukemia; 2005 Oct; 19(10):1818-23. PubMed ID: 16094418
[TBL] [Abstract][Full Text] [Related]
23. NCCN preliminary non-Hodgkin's lymphoma practice guidelines.
Oncology (Williston Park); 1997 Nov; 11(11A):281-46. PubMed ID: 9430195
[No Abstract] [Full Text] [Related]
24. Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target.
Gould C; Lickiss J; Kankanige Y; Yerneni S; Lade S; Gandhi MK; Chin C; Yannakou CK; Villa D; Slack GW; Markham JF; Tam CS; Nelson N; Seymour JF; Dickinson M; Neeson PJ; Westerman D; Blombery P
Br J Haematol; 2021 Oct; 195(1):113-118. PubMed ID: 34426978
[TBL] [Abstract][Full Text] [Related]
25. Nodal and splenic marginal zone B cell lymphomas.
Mollejo M; Camacho FI; Algara P; Ruiz-Ballesteros E; García JF; Piris MA
Hematol Oncol; 2005; 23(3-4):108-18. PubMed ID: 16307458
[TBL] [Abstract][Full Text] [Related]
26. [Treatment strategy for indolent B-cell lymphoma].
Tobinai K
Rinsho Ketsueki; 2001 Apr; 42(4):288-92. PubMed ID: 11400299
[No Abstract] [Full Text] [Related]
27. Hepatitis C virus - associated B cell non-Hodgkin's lymphoma.
Mihăilă RG
World J Gastroenterol; 2016 Jul; 22(27):6214-23. PubMed ID: 27468211
[TBL] [Abstract][Full Text] [Related]
28. How we treat mature B-cell neoplasms (indolent B-cell lymphomas).
Lumish M; Falchi L; Imber BS; Scordo M; von Keudell G; Joffe E
J Hematol Oncol; 2021 Jan; 14(1):5. PubMed ID: 33407745
[TBL] [Abstract][Full Text] [Related]
29. Introduction to a review series: the paradox of indolent B-cell lymphoma.
Sehn LH
Blood; 2016 Apr; 127(17):2045-6. PubMed ID: 26989203
[No Abstract] [Full Text] [Related]
30. Somatic hypermutation and B-cell lymphoma.
Dunn-Walters D; Thiede C; Alpen B; Spencer J
Philos Trans R Soc Lond B Biol Sci; 2001 Jan; 356(1405):73-82. PubMed ID: 11205334
[TBL] [Abstract][Full Text] [Related]
31. Primary cutaneous B-cell lymphomas: part II. Therapy and future directions.
Suárez AL; Querfeld C; Horwitz S; Pulitzer M; Moskowitz A; Myskowski PL
J Am Acad Dermatol; 2013 Sep; 69(3):343.e1-11; quiz 355-6. PubMed ID: 23957985
[TBL] [Abstract][Full Text] [Related]
32. Hematopathology approaches to diagnosis and prognosis of indolent B-cell lymphomas.
Gascoyne RD
Hematology Am Soc Hematol Educ Program; 2005; ():299-306. PubMed ID: 16304395
[TBL] [Abstract][Full Text] [Related]
33. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
[TBL] [Abstract][Full Text] [Related]
34. Genomic signatures in B-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?
Iqbal J; Naushad H; Bi C; Yu J; Bouska A; Rohr J; Chao W; Fu K; Chan WC; Vose JM
Blood Rev; 2016 Mar; 30(2):73-88. PubMed ID: 26432520
[TBL] [Abstract][Full Text] [Related]
35. Targeting indolent non-Hodgkin lymphoma.
Leslie LA; Skarbnik AP; Bejot C; Stives S; Feldman TA; Goy AH
Expert Rev Hematol; 2017 Apr; 10(4):299-313. PubMed ID: 28277849
[TBL] [Abstract][Full Text] [Related]
36. Indolent lymphomas other than follicular and marginal zone lymphomas.
Peinert S; Seymour JF
Hematol Oncol Clin North Am; 2008 Oct; 22(5):903-40, viii. PubMed ID: 18954743
[TBL] [Abstract][Full Text] [Related]
37. Recurrent mutations in genes involved in nuclear factor-κB signalling in nodal marginal zone lymphoma-diagnostic and therapeutic implications.
van den Brand M; Rijntjes J; Hebeda KM; Menting L; Bregitha CV; Stevens WB; van der Velden WJ; Tops BB; van Krieken JH; Groenen PJ
Histopathology; 2017 Jan; 70(2):174-184. PubMed ID: 27297871
[TBL] [Abstract][Full Text] [Related]
38. Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma.
Villa D; George A; Seymour JF; Toze CL; Crump M; Lee C; Buckstein R; Stewart DA; MacDonald D; Foley R; Xenocostas A; Sabloff M; Chua N; Couture F; Larouche JF; Cohen S; Savage KJ; Connors JM; Panzarella T; Carney DA; Dickinson M; Kuruvilla J
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1813-8. PubMed ID: 25042735
[TBL] [Abstract][Full Text] [Related]
39. Transformation of indolent B-cell lymphomas.
Montoto S; Fitzgibbon J
J Clin Oncol; 2011 May; 29(14):1827-34. PubMed ID: 21483014
[TBL] [Abstract][Full Text] [Related]
40. Histogenesis and pathogenesis of follicular small cleaved cell lymphoma (FSCCL), diffuse small cleaved cell lymphoma (DSCCL) and intermediate lymphocytic lymphoma/lymphocytic lymphoma of intermediate differentiation (ILL/IDL).
Abe M; Wakasa H
Fukushima J Med Sci; 1994 Dec; 40(2):85-101. PubMed ID: 7642169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
